+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Non-Hodgkin Lymphoma (Oncology) - Drugs in Development, 2021

  • ID: 5473068
  • Report
  • October 2021
  • Region: Global
  • 4641 Pages
  • Global Markets Direct
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

FEATURED COMPANIES

  • 3SBio Inc
  • 4SC AG
  • AB Science SA
  • AbbVie Inc
  • ABIONYX Pharma SA..
  • Abologix Sarl
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Hodgkin Lymphoma - Drugs In Development, 2021, provides an overview of the Non-Hodgkin Lymphoma (Oncology) pipeline landscape. Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body’s immune system. Symptoms depend on what area of the body is affected by the cancer and how fast the cancer is growing. Symptoms may include night sweats (soaking the bed sheets and pajamas even though the room temperature is not too hot),fever and chills that come and go, itching, swollen lymph nodes in the neck, underarms, groin, or other areas, weight loss, coughing or shortness of breath if the cancer affects the thymus gland or lymph nodes in the chest, putting pressure on the windpipe (trachea) or other airway, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if the cancer affects the brain. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights


This pipeline guide provides comprehensive information on the therapeutics under development for Non-Hodgkin Lymphoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Non-Hodgkin Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Hodgkin Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 23, 2, 44, 230, 239, 14, 28, 210, 35 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages comprises 33, 47, 3, 39, 5 and 1 molecules, respectively.

Non-Hodgkin Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Hodgkin Lymphoma (Oncology)
  • The pipeline guide reviews pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities
  • The pipeline guide reviews key companies involved in Non-Hodgkin Lymphoma (Oncology) therapeutics and enlists all their major and minor projects
  • The pipeline guide evaluates Non-Hodgkin Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects
  • The pipeline guide reviews latest news related to pipeline therapeutics for Non-Hodgkin Lymphoma (Oncology)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Find and recognize significant and varied types of therapeutics under development for Non-Hodgkin Lymphoma (Oncology)
  • Classify potential new clients or partners in the target demographic
  • Develop tactical initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics
  • Formulate corrective measures for pipeline projects by understanding Non-Hodgkin Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 3SBio Inc
  • 4SC AG
  • AB Science SA
  • AbbVie Inc
  • ABIONYX Pharma SA..
  • Abologix Sarl

Introduction
Non-Hodgkin Lymphoma - Overview
  • Non-Hodgkin Lymphoma - Therapeutics Development
  • Non-Hodgkin Lymphoma - Therapeutics Assessment
  • Non-Hodgkin Lymphoma - Companies Involved in Therapeutics Development
  • Non-Hodgkin Lymphoma - Drug Profiles
  • Non-Hodgkin Lymphoma - Dormant Projects
  • Non-Hodgkin Lymphoma - Discontinued Products
  • Non-Hodgkin Lymphoma - Product Development Milestones

Appendix
List of Tables
  • Number of Products under Development for Non-Hodgkin Lymphoma, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Non-Hodgkin Lymphoma - Pipeline by 3SBio Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by 4SC AG, 2021
  • Non-Hodgkin Lymphoma - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, 2021
  • Non-Hodgkin Lymphoma - Pipeline by AB Science SA, 2021
  • Non-Hodgkin Lymphoma - Pipeline by AbbVie Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by ABIONYX Pharma SA, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Abologix Sarl, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Acerta Pharma BV, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Actinium Pharmaceuticals Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Actinobac Biomed Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Adagene Suzhou Ltd, 2021
  • Non-Hodgkin Lymphoma - Pipeline by ADC Therapeutics SA, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Adicet Bio Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Adienne Pharma & Biotech SA, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Adlai Nortye Biopharma Co Ltd, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Advenchen Laboratories LLC, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Affimed GmbH, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Affitech A/S, 2021
  • Non-Hodgkin Lymphoma - Pipeline by AGC Biologics SpA, 2021
  • Non-Hodgkin Lymphoma - Pipeline by AI Therapeutics Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Akeso Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Aleta Biotherapeutics Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Alexion Pharmaceuticals Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Alfasigma SpA, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Allogene Therapeutics Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Alphamab Oncology, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Alpine Immune Sciences Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by ALX Oncology Holdings Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Amgen Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Anew Oncology Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Angimmune LLC, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Angiocrine Bioscience Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Anhorn Medicines Co Ltd, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Antengene Corp Ltd, 2021
  • Non-Hodgkin Lymphoma - Pipeline by AP Biosciences Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Apollomics Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Apotex Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Applied Therapeutics Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Aprea Therapeutics Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Archigen Biotech Ltd, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Arcus Biosciences Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Ardan Pharma, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Argenx SE, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Ascentage Pharma Group International, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Astellas Pharma Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Astex Pharmaceuticals Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by AstraZeneca Plc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by AUM Biosciences Pte Ltd, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Aurigene Discovery Technologies Ltd, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Autolus Therapeutics Plc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Avalon GloboCare Corp, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Avesthagen Ltd, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Avipep Pty Ltd, 2021
  • Non-Hodgkin Lymphoma - Pipeline by AVM Biotechnology LLC, 2021
  • Non-Hodgkin Lymphoma - Pipeline by AzarGen Biotechnologies (Pty) Ltd, 2021
  • Non-Hodgkin Lymphoma - Pipeline by BAKX Therapeutics Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Bantam Pharmaceutical LLC, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Bayer AG, 2021
  • Non-Hodgkin Lymphoma - Pipeline by BeiGene Ltd, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Beijing Cytoheal Biotech Co Ltd, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Beijing Gaobo Biotechnology Co Ltd, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Beijing GD Initiative Cell Therapy Technology Co Ltd, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Celularity Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Elicera Therapeutics AB, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Emmaus Life Sciences Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Enterome Bioscience SA, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Epidestiny Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Epizyme Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by ERYTECH Pharma SA, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Esanex Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Eternity Bioscience Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Eucure (Beijing) Biopharma Co Ltd, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Eureka Therapeutics Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Eutilex Co Ltd, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Evive Biotech, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Evotec SE, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Excelmab Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Magenta Therapeutics Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by ManysmarT Therapeutics Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Marino Biotechnology Co Ltd, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Marker Therapeutics Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Meabco AS, 2021
  • Non-Hodgkin Lymphoma - Pipeline by MedC Biopharma Ltd, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Medinet Co Ltd, 2021
  • Non-Hodgkin Lymphoma - Pipeline by MediSix Therapeutics Pte Ltd, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Meditope Biosciences Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Medivir AB, 2021
  • Non-Hodgkin Lymphoma - Pipeline by MedPacto Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by MEI Pharma Inc, 2021
  • Non-Hodgkin Lymphoma - Pipeline by MENTRIK Biotech LLC, 2021
  • Non-Hodgkin Lymphoma - Pipeline by Merck & Co Inc, 2021

List of Figures
  • Number of Products under Development for Non-Hodgkin Lymphoma, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • 3SBio Inc
  • 4SC AG
  • A. Menarini Industrie Farmaceutiche Riunite Srl .
  • AB Science SA
  • AbbVie Inc
  • ABIONYX Pharma SA..
  • Abologix Sarl
  • Acerta Pharma BV
  • Actinium Pharmaceuticals Inc
  • Actinobac Biomed Inc
  • Adagene Suzhou Ltd
  • ADC Therapeutics SA
  • Adicet Bio Inc
  • Adienne Pharma & Biotech SA
  • Adlai Nortye Biopharma Co Ltd
  • Advenchen Laboratories LLC
Note: Product cover images may vary from those shown